Phase 3 data for PCSK9 inhibitor wows

Nat Biotechnol. 2013 Dec;31(12):1057-8. doi: 10.1038/nbt1213-1057.
No abstract available

Publication types

  • News

MeSH terms

  • Clinical Trials, Phase III as Topic*
  • Humans
  • Hypercholesterolemia / diagnosis*
  • Hypercholesterolemia / prevention & control*
  • Hypolipidemic Agents / adverse effects*
  • Hypolipidemic Agents / therapeutic use*
  • Proprotein Convertase 9
  • Proprotein Convertases / antagonists & inhibitors*
  • Serine Endopeptidases
  • Treatment Outcome

Substances

  • Hypolipidemic Agents
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases